The FDA has issued draft guidance to help pharmaceutical companies enroll more participants from underrepresented populations into clinical trials.
That’s a challenge that New Haven-based Jumo Health, a global health education company, has been helping to address.
By 2015, the company had attracted the attention — and investment — of venture capitalists, who brought in a new management team, including current President and CEO Kevin Aniskovich.